New combination for liver cancer after immunotherapy stops working
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three treatments for advanced liver cancer that has not responded to immunotherapy: a chemotherapy delivered directly to the liver (HAIC), an immunotherapy drug (PD-L1), and a targeted therapy pill (Regorafenib). The goal is to see if this new combination can help control the cancer when the first immunotherapy stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that is confirmed by imaging or biopsy.
- You have already tried a PD-1/PD-L1 immunotherapy drug (like pembrolizumab or nivolumab) and it stopped working.
- You have at least one tumor that can be measured on a scan.
- You are expected to live at least 3 more months and are able to care for yourself (ECOG 0-1).
- Your liver function is good (Child-Pugh grade A, score 5-6).
- You have not taken Regorafenib before, and you have not had serious side effects from immunotherapy that required stopping it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests whether combining two medicines (trastuzumab and regorafenib) works better than regorafenib alone for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if the combination helps control the cancer longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests regorafenib, a targeted therapy, for people with advanced liver cancer that progressed after first-line immunotherapy. It aims to slow tumor growth and may offer a new option when standard treatment stops working.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.